Latest

Announcement of EMA Relocation Prompts Reaction

UK commentators point to job losses and disruption to patients following news that the European Medicines Agency (EMA) will be relocated to Amsterdam.

QIDP: An Insufficient Policy?

The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.

Multidisciplinary Care Teams: Challenge or Opportunity?

Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.

Pharm Exec's 2018 Pipeline Report

Analysis shows that persistence is paying off for drug developers, driven by the rise of CAR-T and other gene therapy, newly discovered cancer targets, better patient identification methods—and the realization that failures have their place in shaping the pipeline of tomorrow.

PharmExec Videos

New & Noteworthy

Abbott: Why Branded Generics Matter

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.

Rewarding Creative Thinking in Oncology: The Astellas C3 Prize

Mark Reisenauer, SVP, Oncology Business Unit at Astellas, tells PharmExec about the development and objectives of the Astellas Oncology C3 Prize.

Taiwan’s Biotech Boom

With its convergence of healthcare talent and tech, the nation is turning into a prime destination for innovative startups.

Driving Decisions with Data: Sundeep Bhan, CEO, Prognos

Prognos CEO Sundeep Bhan talks about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

FDA Works to Get Pharma Up and Running in Puerto Rico

While most pharma companies are in partial production using generators, few are operating at 100% capacity, writes Jill Wechsler.

Sales & Marketing

Multidisciplinary Care Teams: Challenge or Opportunity?

Abigail Bernardi explains how a better understanding of connections among practitioners on care teams helps sales reps build relationships while benefitting a company’s marketing efforts.

Pharma Companies Can Solve the Social Media Adverse Events Reporting Problem and Stop Worrying

Organizations can now confidently leverage social media and messaging platforms to market and share content, writes Dawn Lacallade.

Did Amazon Just Create a Solution to Pharma’s Last Mile Problem?

The internet giant’s latest service may also be another piece of the company’s pharma puzzle.

eBooks

Emerging BioPharma: Your Guide to Clinical and Commercial Considerations

This eBook will focus on the specific needs and concerns of the smaller to mid-size biopharmaceutical company. Articles cover considerations from Phase II to commercial pathways. 

View all eBooks

PEspeaks

Sponsors Work with FDA to Streamline Combo Product Development and Oversight

Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.

Pragmatic Therapy: Balancing Innovation, Cost, and Care

is spectacular science enough to guarantee success for new medicines?

How HEOR Can Claim the Spotlight

If HEOR teams don’t clearly and concisely define themselves, their discipline, and their mission, they risk failure and irrelevance. A thoughtful communications program aimed at colleagues will win them due recognition of the value they bring, a say in key business decisions, and ongoing relevance.

Job Hunter Meet Headhunter (aka Executive Recruiter)

John Sattler offers some tips on engaging executive and professional recruiters.

Compliance Top of Mind

There is never a lack of legal or regulatory issues to keep track of—and worry about—in the life sciences industry. The articles from Pharmaceutical Executive provide a look at the latest in compliance for marketing, labeling, and export control, as well as offer tips to stay compliant in the coming years.
 

Read More.

Interviews

Abbott: Why Branded Generics Matter

Andrew Lane, EVP, Established Pharmaceuticals at Abbott, tells Pharm Exec how understanding emerging market dynamics can explain why branded generic medicines are important.

Rewarding Creative Thinking in Oncology: The Astellas C3 Prize

Mark Reisenauer, SVP, Oncology Business Unit at Astellas, tells PharmExec about the development and objectives of the Astellas Oncology C3 Prize.

Driving Decisions with Data: Sundeep Bhan, CEO, Prognos

Prognos CEO Sundeep Bhan talks about how the company’s unique offering will reach beyond life sciences as the long-promised benefits of AI become reality.

Regulatory

Sponsors Work with FDA to Streamline Combo Product Development and Oversight

Jill Wechsler discusses the hot topic of how FDA should oversee combination products that incorporate a digital health component.

QIDP: An Insufficient Policy?

The GAIN Act creates a process for the Qualified Infectious Disease Product (QIDP) designation, which provides incentives for developing antimicrobial therapies for combating resistant organisms. But while the program has been successful in driving innovation, commercial viability remains a question.

FDA Works to Get Pharma Up and Running in Puerto Rico

While most pharma companies are in partial production using generators, few are operating at 100% capacity, writes Jill Wechsler.

From the Editor

No Overnight Successes

Our annual look at the drug industry's pipeline—the progress and the setbacks—puts my thoughts on those people driving new science behind the scenes in pharmaceutical research.

Inspiring People, Inspiring Teams

As we again highlight a roster of emerging leaders in pharma, I wanted to recognize Pharm Exec's own unique team behind the scenes.

lorem ipsum